UNLABELLED: Clinical application of the prognostic gene expression signature has been delayed due to the large number of genes and complexity of prediction algorithms. In the current study we aimed to develop an easy-to-use risk score with a limited number of genes that can robustly predict prognosis of patients with hepatocellular carcinoma (HCC). The risk score was developed using Cox coefficient values of 65 genes in the training set (n = 139) and its robustness was validated in test sets (n = 292). The risk score was a highly significant predictor of overall survival (OS) in the first test cohort (P = 5.6 × 10(-5), n = 100) and the second test cohort (P = 5.0 × 10(-5) , n = 192). In multivariate analysis, the risk score was a significant risk factor among clinical variables examined together (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.13-1.64; P = 0.001 for OS). CONCLUSION: The risk score classifier we have developed can identify two clinically distinct HCC subtypes at early and late stages of the disease in a simple and highly reproducible manner across multiple datasets.
UNLABELLED: Clinical application of the prognostic gene expression signature has been delayed due to the large number of genes and complexity of prediction algorithms. In the current study we aimed to develop an easy-to-use risk score with a limited number of genes that can robustly predict prognosis of patients with hepatocellular carcinoma (HCC). The risk score was developed using Cox coefficient values of 65 genes in the training set (n = 139) and its robustness was validated in test sets (n = 292). The risk score was a highly significant predictor of overall survival (OS) in the first test cohort (P = 5.6 × 10(-5), n = 100) and the second test cohort (P = 5.0 × 10(-5) , n = 192). In multivariate analysis, the risk score was a significant risk factor among clinical variables examined together (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.13-1.64; P = 0.001 for OS). CONCLUSION: The risk score classifier we have developed can identify two clinically distinct HCC subtypes at early and late stages of the disease in a simple and highly reproducible manner across multiple datasets.
Authors: Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub Journal: N Engl J Med Date: 2008-10-15 Impact factor: 91.245
Authors: Yun-Yong Park; Bo Hwa Sohn; Randy L Johnson; Myoung-Hee Kang; Sang Bae Kim; Jae-Jun Shim; Lingegowda S Mangala; Ji Hoon Kim; Jeong Eun Yoo; Cristian Rodriguez-Aguayo; Sunila Pradeep; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Woojin Jeong; Inn Sun Park; Young Nyun Park; Anil K Sood; Gordon B Mills; Ju-Seog Lee Journal: Hepatology Date: 2015-11-26 Impact factor: 17.425
Authors: Gholamreza Bidkhori; Rui Benfeitas; Martina Klevstig; Cheng Zhang; Jens Nielsen; Mathias Uhlen; Jan Boren; Adil Mardinoglu Journal: Proc Natl Acad Sci U S A Date: 2018-11-27 Impact factor: 11.205
Authors: Yuri V Postnikov; Takashi Furusawa; Diana C Haines; Valentina M Factor; Michael Bustin Journal: Mol Cancer Res Date: 2013-12-02 Impact factor: 5.852